ArticleScience immunology2022
Myeloid cell tropism enables MHC-E-restricted CD8
Open access · greenAbstract read
In one paragraph
Article in Science immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 40 citations in OpenAlex.
- Initial sites of SIV rebound after antiretroviral treatment cessation in rhesus macaques.Nature microbiology · 2026Article
- CD8+ T cells cross-restricted by HLA-B*57 and HLA-E*01 recognize HIV Gag with different functional profiles.JCI insight · 2026Article
- The race between viral immune evasion and the MHC class I antigen processing pathway.FEMS microbiology reviews · 2026Review
- Accelerating Innovation: Advancing Opportunities in HIV Vaccine Development.Current HIV research · 2026Review
- The murine MHC-E molecule Qa-1Frontiers in immunology · 2026Article
- Targeting MHC-E as a new strategy for vaccines and immunotherapeutics.Nature reviews. Immunology · 2026Review
- T cell antigenic recognition sequencing (TAR-seq) enables precise characterization of vaccine-elicited cellular immunity ex vivo andFrontiers in immunology · 2026Article
- The Expanding Role of HLA-E in Host Defense: A Target for Broadly Applicable Vaccines and Immunotherapies.Cells · 2025Review
- A cytoplasmic motif in HLA-E that drives clathrin-mediated endocytosis and VCP-associated postendocytic trafficking.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Glycoprotein L-deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E-restricted CD8+ T cells that protect against SIV.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Can Humanized Immune System Mouse and Rat Models Accelerate the Development of Cytomegalovirus-Based Vaccines Against Infectious Diseases and Cancers?International journal of molecular sciences · 2025Review
- The pentameric complex is not required for congenital CMV transmission in seronegative rhesus macaques.Science translational medicine · 2025Article
- Why Are Cytomegalovirus-Encoded G-Protein-Coupled Receptors Essential for Infection but Only Variably Conserved?Pathogens (Basel, Switzerland) · 2025Review
- Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine.Vaccines · 2025Review
- Combining a rhesus cytomegalovirus/SIV vaccine with a neutralizing antibody to protect against SIV challenges in rhesus macaques.Frontiers in microbiology · 2025Article
- HLA-E: Immune Receptor Functional Mechanisms Revealed by Structural Studies.Immunological reviews · 2025Review
- Proceedings of the Conference "CMV Vaccine Development-How Close Are We?" (27-28 September 2023).Vaccines · 2024Article
- Human cytomegalovirus UL18 prevents priming of MHC-E- and MHC-II-restricted CD8Science immunology · 2024Article
- Regulation of the cell surface expression of classical and non-classical MHC proteins by the human cytomegalovirus UL40 and rhesus cytomegalovirus Rh67 proteins.Journal of virology · 2024Article
- Cytomegalovirus vaccine vector-induced effector memory CD4 + T cells protect cynomolgus macaques from lethal aerosolized heterologous avian influenza challenge.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 3 institutions in 1 country.
Scott G HansenVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-9845-6481
Meaghan H HancockVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-2945-0147
Daniel MalouliVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-1287-7283
Emily E MarshallVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-4049-8934
Colette M HughesVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.
Kurt T RandallVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.
David MorrowVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-4686-830X
Julia C FordVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-4989-2842
Roxanne M GilbrideVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.
Andrea N SelsethVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0001-9536-463X
Renee Espinosa TrethewyVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.
Lindsey M BishopVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0001-6876-6510
Kelli OswaldAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.ORCID 0000-0002-6638-2625
Rebecca ShoemakerAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.
Brian BerkemeierAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.ORCID 0000-0003-1215-5694
William J BoscheAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.ORCID 0000-0001-5367-2116
Michael HullAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.
Lorna SilipinoAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.ORCID 0000-0001-8022-5151
Michael NekorchukVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.
Kathleen Busman-SahayVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-8549-0023
Jacob D EstesVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-9652-6394
Michael K AxthelmVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-1984-5906
Jeremy SmedleyVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-3369-4662
Danica ShaoVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Paul T EdlefsenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0002-8393-8103
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD 21702, USA.ORCID 0000-0002-9494-0268
Klaus FrühVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0001-8014-3877
Jay A NelsonVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.
Louis J PickerVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-0546-398X
Oregon National Primate Research Center · USFrederick National Laboratory for Cancer Research · USFred Hutch Cancer Center · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MSDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9MUpgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9MConsortia for Innovative AIDS Research in Nonhuman PrimatesUM1AI124377 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., PICKER, LOUIS J. · 2016 to 2021
$53.0MPhase 2 Enhancement of Outdoor Group Housing for U42 SPF 9 Rhesus MacaquesU42OD023038 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI RUDOLF Paul BOHM, Lauren Drew Martin · 2016 to 2026
$21.9MVirology and Vector Production Core CU19AI128741 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2017 to 2021
$11.8MViral Testing CoreU42OD010426 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Andrew Haertel, Lauren Drew Martin · 2013 to 2026
$6.0MCCR NIH HHS HHSN261200800001CNCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261200800001ENIAID NIH HHS U19 AI128741NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI124377NIH HHS P51 OD011092NIH HHS U42 OD010426NIH HHS U42 OD023038
Abstract
The strain 68-1 rhesus cytomegalovirus (RhCMV)-based vaccine for simian immunodeficiency virus (SIV) can stringently protect rhesus macaques (RMs) from SIV challenge by arresting viral replication early in primary infection. This vaccine elicits unconventional SIV-specific CD8
Indexed as
Cytomegalovirus VaccinesMicroRNAsSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsCD8-Positive T-LymphocytesCytomegalovirusEpitopesMacaca mulattaMajor Histocompatibility ComplexMyeloid CellsTropismVaccine EfficacyCytomegalovirus VaccinesEpitopesMicroRNAsSAIDS Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.